Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ex-Genentech staff indicted for JHL help

Executive Summary

A federal grand jury has indicted three former Genentech employees and a former JHL Biotech staff member for stealing trade secrets from the originator and funnelling them to the Taiwanese biosimilars player to help it develop biosimilars of four of Genentech’s products: Rituxan (rituximab), Herceptin (trastuzumab), Pulmozyme (dornase alfa), and Avastin (bevacizumab).

You may also be interested in...



Former JHL Executives Face Prison Over Trade Secrets Theft

Two former JHL Biotech executives have been handed prison sentences after pleading guilty to a charge of conspiracy to commit theft of trade secrets and wire fraud, in relation to the Taiwanese firm’s development of multiple biosimilars.

Patent Filing By Former Employees Leads Pfizer To File Trade Secret Suit

Pfizer claims two former employees stole trade secrets relating to its diabetes-obesity GLP-1 receptor agonist research program for their startup Regor Therapeutics. Regor’s $1.5bn deal with Lilly further spurred Pfizer’s concerns.

Employee’s Decoy Laptop Did Not Trick Pfizer Security, Trade Secret Suit Says

Pfizer alleges its associate director of statistics transferred 12,000 files from her company laptop ahead of move to Xencor. Company seeks a temporary restraining order to prevent her from disclosing confidential information, including information on Pfizer’s COVID-19 vaccine and monoclonal antibodies for treatment of cancer.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel